Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib
Huali Wang, Xue Ma, Xin‐Yuan Guan, Chen Song, Guo‐Bo Li, Yamei Yu, Lingling Yang
Topics & Concepts
SorafenibSynthetic lethalitySIRT2Cancer researchCancerBreast cancerCancer cellMedicinePharmacologySirtuinChemistryInternal medicineAcetylationBiochemistryHepatocellular carcinomaDNA repairGeneSirtuins and Resveratrol in MedicineCancer Treatment and PharmacologyCalcium signaling and nucleotide metabolism